TLX · Telix Pharmaceuticals Limited

16.84

AUD

0.08 (0.477%)

19/08/2026 04:10:13 PM

Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

AU$5.72B

3026.10

EV/EBITDA

69.7

DIV Yield

0%

Franking

0%

MQV Rating

5Very Weak

As at 19/08/2026 04:10:13 PM

Price Chart

Description

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

All-Companies
All-Consensus
ALL-Recommendations
Consensus Cheap
Defying Gravity
GROWTH AUS
HALO 100
HALO 200
HALO Ords
HALO Price Momentum
Short Term Trend - Long

Key Fundamentals

EPS 3 yr Growth

-90.90%

EBITDA Margin

4.90%

Operating Cashflow

-$17m

Free Cash Flow Return

-2.20%

ROIC

-0.90%

Interest Coverage

1.10

Quick Ratio

1.30

Performance

52 weeks range

Low 8.26 - 19.07

Trade Value (12mth)

US$5,907,917.00

1 week

-1.12%

1 month

9.47%

YTD

47.54%

1 year

-8.57%

All time high

31.97

Additional Data

Shares Outstanding (Fully Diluted)

339m

HALO Sector

Healthcare

Next Company Report Date

19-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

10.75

Consensus

Unlock full consensus

Consensus score

/10

Recommendation

Buy

Target price

Deviation

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Very Strong

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Weak

Mqv Small

Neutral

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Weak

Balance Sheet

Very Weak

Valuation

Unlock full dataset

Value

Consensus

Yield

News & Announcements

Date	Event
31 July 26ASXD
24 July 26ASXD
21 July 26ASXD
10 July 26ASXD
10 July 26ASXD

Key Stakeholders

Name	Title
Christian P. Behrenbruch	Individual
Andreas Kluge	Individual
Grand Pharmaceutical Group Ltd.	Public Company
UV-Cap Verwaltungs GmbH	Private Company
Mark Nelson	Individual